Alx oncology reports fourth quarter and full year 2020 financial results and provides clinical development and operational highlights and upcoming milestones

Burlingame, calif., march 18, 2021 (globe newswire) -- alx oncology holdings inc., (“alx oncology”) (nasdaq: alxo) a clinical-stage immuno-oncology company developing therapies that block the cd47 checkpoint pathway, today reported financial results for the fourth quarter and year ended december 31, 2020 and provided clinical development and operational highlights.
ALXO Ratings Summary
ALXO Quant Ranking